Your Directors' have pleasure in presenting Annual Report together with the Audited
Accounts of the Company for the year ended 31^st March, 2024.

1. FINANCIAL RESULTS

Your Company financial performance during the year 2023-24 is summarized below:

(Rs. In Thousands)

2. FINANCIAL SUMMARY

The Company earned income from operation of Rs. 11309.35 (in thousands) during the
FY 2023-24, as compared to the income from operation of Rs. 11617.79 (in thousands)
earned in the previous FY 2022-23. The Company's Net Profit for the Financial Year
ended March 31, 2024 stood at Rs. 302.09 (in thousands) as against a Net loss of Rs. Rs.
785.51 (in thousands) in the previous year.

3. CHANGE IN NAME OF THE COMPANY

During the financial year under review, there is no change in the name of the Company.

4. CHANGE IN NATURE OF BUSINESS

During the financial year under review, there is no change in the nature of business of
the Company.

5. TRANSFER TO RESERVES

No amount has been transferred to Reserves during the year under review.

6. CHANGES IN SHARE CAPITAL

The Authorised Share Capital of the Company is Rs.8,20,00,000/- divided into 82,00,000
equity shares of Rs. 10/- each and the paid-up share capital of the Company is
Rs.5,46,83,000/- divided into 54,68,300 equity shares of Rs. 10/- each.

The Company has not issued any kind of shares or securities during the year under
review.

7. DIVIDEND

The Board of Directors expressed their inability to recommend any dividend on equity
shares for the year ended March 31, 2024.

8. PUBLIC DEPOSITS

During the year, the Company has not accepted any deposits from public nor during the
previous financial year.

9. BUY-BACK / SWEAT EQUITY / BONUS SHARES

The Company has neither bought back its shares nor has issued any sweat equity or
Bonus shares during the year under review.

10. EMPLOYEES STOCK OPTION PLAN

The Company has not provided any Stock Option Scheme to the Employees.

11. ISSUE OF DEBENTURES, BONDS OR ANY NON-CONVERTIBLE SECURITIES

The Company has not issued any debenture, bonds or non-convertible securities.

12. STATUTORY AUDITORS

The Members had appointed M/s. DD & Company (erstwhile M/s. Dinesh H. Agarwal &
Company)., Chartered Accountants, as Statutory Auditor of the Company at the Annual
General Meeting held on September 29, 2018 and September 30, 2021 for a period of
five years in aggregate from FY 2018-19 to FY 2022-2023.

The term of Statutory Auditor will end at the ensuing Annual General Meeting ("AGM")
of the Company and the Company is required to appoint new Statutory Auditors.

Pursuant to section 139 of the Companies Act, 2013 the Board in its meeting held on
August 30, 2023 has recommended the appointment of M/s. L K Ajmera & Associates
Chartered Accountants as new Statutory Auditor of the company to hold office for a
period of five (5) financial years (for FY 2023-2024 till FY 2027-2028), i.e from conclusion
of this Annual General Meeting till conclusion of Annual General Meeting to be held in
the year 2028, at a remuneration to be determined by the Board of Directors and
Auditors.

13. INTERNAL AUDITOR

In the Board Meeting held on August 30, 2023, Ms. Ankita Agawane, Internal Auditor of
the company had resigned and the Board appointed new Internal Auditor Mr. Arun
Mulya for a period of three years from FY 2023-2024 to FY 2025-2026.

14. STATUTORY AUDIT REPORT

The Auditors' Report on the financial statement for the current year is self-explanatory,
therefore does not require any further explanation. The Company has already
submitted declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligation and
Disclosure Requirements) Regulations, 2015 to the Stock Exchange(s).

15. COST AUDITOR REPORT AND COST RECORD

Appointment of Cost Auditor and maintenance of cost records is not applicable to the
company.

16. SECRETARIAL AUDITOR AND SECRETARIAL AUDIT REPORT

M/s. Maithili Nandedkar & Associates, Practicing Company Secretaries, appointed as
Secretarial Auditor in the Board Meeting held on held on August 12, 2021 to conduct
the Secretarial Audit for the 3 (Three) financial years FY 2021-22 till FY 2023-24. Later
on, M/s. Maithili Nandedkar & Associates changed their firm name to M/s. MNB &
Co. LLP.

Therefore, M/s. MNB & Co. LLP, Practising Company Secretaries are the secretarial
auditor for the financial year 2022-2023 and 2023-2024.

Further, the Board of Directors in their meeting held on May 25, 2024 have re¬
appointed M/s. MNB & Co. LLP, Practising Company Secretaries for a further period of 3
years i.e. F.Y. 2024-2025 upto F.Y 2026-2027.

The Secretarial Audit Report for the Financial Year 2023-2024 forms part of the Annual
Report. The Secretarial Auditors' Report presented to the Members for the year under
review is qualified and is annexed to this Report.

The Secretarial Audit report for the current year is self-explanatory, therefore does not
require any further explanation and listing fees has not paid due to financial crises faced
by the company.

17. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB-SECTION (12)
OF SECTION 143

There are no frauds reported by the Statutory Auditors of the Company under Section
143 (12).

18. DIRECTORS AND KEY MANAGERIAL PERSONNEL

In accordance with the Companies Act, none of the Directors are liable to retire by
rotation at the ensuing Annual General Meeting.

Ms. Komal Behl, Company Secretary, has tendered her resignation effective January 24,
2024. As on date, the Company does not have a Company Secretary.

Ms. Abha Rajesh Kapoor (DIN: 02799429) was re-appointed as Whole-Time Director of
the Company for further period of 3 years w.e.f. June 14, 2023 till June 13, 2026

Subsequent to year under review, Mr. Sunil Khandelwal has been ceased to be a
Director of the Company due to expiry of his tenure.

Also, Mr. Gopal Kumar Sahu has been re-appointed as Independent Director of the
Company for a period of 5 years subject to the approval of the shareholders in the
ensuing General Meeting of the Company.

19. ANNUAL RETURN

The Annual Return for the financial year ended March 31, 2024 along with Notice of
AGM is being uploaded on the website of the Company. The web link for the same is as
under: https://www.rubramed.com/extract-annual-return.html

20. DETAILS OF SUBSIDIARIES/ASSOCIATES/JOINT VENTURES, IF ANY:

As on March 31, 2024, the Company does not have any subsidiary, associate or joint
venture.

21. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION & FOREIGN EXCHANGE
EARNINGS AND OUTGO

The information pertaining to Conservation of Energy, Technology Absorption and
Foreign Exchange earnings and outgo as required under section 134(3)(m) of the
Companies Act, 2013 read with rule 8(3) of the Companies (Accounts) Rules, 2014 is
annexed to this report as Annexure II.

22. VIGIL MEGHANISM

The Company has established a Vigil Mechanism that enables the Directors and
Employees to report genuine concerns. The Vigil Mechanism provides for

(a) adequate safeguards against victimization of persons who use the Vigil Mechanism;
and

(b) direct access to the Chairperson of the Audit Committee of the Board of Directors of
the Company in appropriate or exceptional cases.

The web link for the policy is as under:

https://www.rubramed.com/policies/Vigil-Mechanism-Policy.pdf

23. CORPORATE SOCIAL RESPONSIBILITY

The provisions of Corporate Social Responsibility are not applicable to the Company as
it does not fall within the purview of Section 135(1) of the Companies Act, 2013.

24. RELATED PARTY TRANSACTIONS

There were no contracts or arrangements entered into by the Company with related
parties referred to in sub-section (1) of section 188 of the Companies Act, 2013. The
related party transactions as per IND AS 24 are given in the notes to the financial
accounts and forms part of the Annual Report.

The policy on Related Party Transactions is part of the website of the Company. The
web link for the policy on related party transaction is as under:
https://www.rubramed.com/policies/Related-Party-Transaction.pdf

25. RISK MANAGEMENT

The Company has devised and implemented a mechanism for risk management.

26. FAMILIARIZATION PROGRAMME FOR INDEPENDENT DIRECTORS

The Company proactively keeps its Directors informed of the activities of the Company,
its management and operations and provides an overall industry perspective as well as
issues being faced by the industry. Details of the Familiarization program for
Independent Directors form part of the website of the Company. The web link of
Familiarization program is as under:

https://www.rubramed.com/policies/Familarisation-of-Independent-Director.pdf

27. MEETING OF BOARD OF DIRECTORS

The details of Board Meeting forms part of Corporate Governance Report.

28. CORPORATE GOVERNANCE

Pursuant to Regulation 15(2) of the Securities Exchange Board of India (Listing
Obligations and Disclosure Requirements) 2015, compliance of Corporate Governance is
not mandatory. However, the company has complied with the provisions of Regulation
17 to 27 of the Securities Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015, to the extent possible. A separate section on
Corporate Governance forms part of the Directors' Report as stipulated in Securities
Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,
2015, is included in the Annual Report as Annexure V.

29. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Management discussion and analysis report is annexed as Annexure VI.

30. STATEMENT OF COMPLIANCE OF APPLICABLE SECRETARIAL STANDARDS:

The Board hereby states that the Company has complied with all the applicable
secretarial standards to the extent possible.

31. INDEPENDENT DIRECTOR'S MEETING

The Board of Directors of the Company meets once in every Financial Year without the
presence of Executive Directors and Management of the Company. The role of the
Directors is as per the provisions of Companies Act, 2013 as well as the Securities
Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,
2015.

32. DECLARATION BY INDEPENDENT DIRECTOR

Pursuant to Section 149(6) of the Companies Act, 2013 and SEBI (Listing Obligation and
Disclosure Requirement) Regulations, 2015, the Independent Directors of the Company
have given the declaration to the Company that they qualify the criteria of
independence as required under the Act.

33. BOARD EVALUATION

Pursuant to the provisions of Companies Act, 2013 and SEBI (Listing Obligation and
Disclosure Requirement) Regulations, 2015, the Board has carried out annual
performance evaluation of its own performance, the directors individually as well the
evaluation of the working of its Audit, Nomination & Remuneration and Stakeholder
committee, including the Chairman of the Board who were evaluated on parameters
such as level of engagement and contribution and independence of judgment thereby
safeguarding the interest of the Company. The performance evaluation of the
Independent Directors was carried out by the entire Board. The performance evaluation
of the Chairman and the Non-Independent Directors was carried out by the

Independent Directors. The Directors expressed their satisfaction with the evaluation
process.

34. PARTICULARS OF LOANS GIVEN, GUARANTEES GIVEN OR INVESTMENTS MADE UNDER
SECTION 186 OF COMPANIES ACT, 2013

Particulars of loans, guarantees and investments made by Company pursuant to Section
186 of the Companies Act, 2013 are given in the notes to the financial accounts forming
part of the Annual Report. The loans and advances made by the Company, during the
financial year under review, are within the limits prescribed in the section 186 of the
Companies Act, 2013.

35. MATERIAL CHANGES BETWEEN THE DATE OF THE BOARD REPORT AND END OF
FINANCIAL YEAR

Subsequent to year under review, there was no change. As per MCA Circular, Current
year AGM is being held through Video Conferencing. Necessary procedure is given in
the AGM Notice. Members are requested to update their Email ID either by writing to
the Company or through the Register or Transfer Agents.

36. MATERIAL DEVELOPMENTS DURING THE FINANCIAL YEAR

Material changes subsequent to the end of the financial year is disclosed herein above.

37. SIGNIFICANT AND / OR MATERIAL ORDERS PASSED BY THE REGULATORS

No significant and/or material order was passed by any Regulator, any Court in India or
any Tribunal, impacting the going concern status and the Company's operations in
future.

38. THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE
INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE YEAR
ALONGWITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR

As on March 31, 2024, there is no proceeding pending under the Insolvency and
Bankruptcy Code, 2016.

39. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE
TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN
FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF

There is no one time settlement done with bank or any financial institution.

40. IN CASE THE SECURITIES ARE SUSPENDED FROM TRADING, THE DIRECTORS REPORT
SHALL EXPLAIN THE REASON THEREOF

The trading of the company has not been suspended.

41. NOMINATION AND REMUNERATION POLICY

An extract of the Company's policy relating to directors appointment, payment of
remuneration and discharge of their duties is annexed herewith. The web link to the
Nomination and Remuneration Policy is as under:

https://www.rubramed.com/policies/NominationandRemunerationPolicy.pdf

42. PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES

The Company does not have any employee/Director who is in receipt of remuneration
exceeding the sum prescribed in Section 197 of the Companies Act, 2013 ("the Act")
read with Rule 5 of the Companies (Appointment and Remuneration of Managerial
Personnel) Rules, 2014.

In terms of the provisions of Section 197(12) of the Act read with Rules 5(2) and 5(3) of
the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014,
a statement showing the names of the top ten employees in terms of remuneration
drawn and names and other particulars of the employees drawing remuneration in
excess of the limits set out in the said rules is available for inspection.

Having regard to the second proviso to rule 5(3) of the Companies (Appointment and
Remuneration of Managerial Personnel) Rules, 2014, such particulars shall be made
available to any shareholder on a specific request made by him in writing before the
date of such Annual General Meeting. Any member interested in obtaining such
information may write to the company. The same is annexed herewith as Annexure- III.

43. A STATEMENT REGARDING OPINION OF THE BOARD WITH REGARD TO INTEGRITY,
EXPERTISE AND EXPERIENCE (INCLUDING THE PROFICIENCY) OF THE INDEPENDENT
DIRECTORS APPOINTED DURING THE YEAR

In the opinion of the board, the independent directors fulfill the conditions specified in
SEBI (LODR) Regulations, 2015, and are independent of the management of the
Company. The Independent Directors have complied with the code prescribed in
schedule IV of the Companies Act, 2013.

44. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE
(PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The company has in place a policy for prevention of sexual harassment in accordance
with the requirements of the Sexual Harassment of women at workplace (Prevention,
Prohibition & Redressal) Act, 2013. Internal Complaints Committee has been set up to
redress complaints received regarding sexual harassment. The Board thereafter
constituted a sexual harassment committee where the chairperson of the Committee is
Ms. Sneha Thakur, and Ms. Abha Kapoor and Mr. Gopal Sahu are the Members. All
employees (permanent, contractual, temporary, trainees) are covered under this policy.

a. number of complaints filed during the financial year - None

b. number of complaints disposed of during the financial year - None

c. number of complaints pending as on end of the financial year - None

45. TRANSFER OF AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND

The Company does not have any funds lying unpaid or unclaimed for a period of seven
years. Therefore, there were no funds which were required to be transferred to
Investor Education and Protection Fund (IEPF).

46. ADEQUACY OF INTERNAL FINANCIAL CONTROLS

The Company has adequate internal financial controls besides timely statutory audit
and limited reviews of performance taking place periodically.

47. REGISTRATION WITH INDEPENDENT DIRECTORS DATABANK

The Independent directors of the company are yet to be registered with Independent
director databank.

48. DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134 of the Act, the Directors state that:

(a) In the preparation of the annual accounts, the applicable accounting standards have
been followed along with proper explanation relating to material departures, if any;

(b) Appropriate accounting policies have been selected and applied consistently and have
made judgments and estimates that are reasonable and prudent, so as to give a true
and fair view of the state of affairs of the Company as at March 31, 2024 and of the
profit for the Company for the year ended March 31, 2024;

(c) Proper and sufficient care has been taken for the maintenance of adequate accounting
records in accordance with the provisions of the Companies Act, 2013 for safeguarding
the assets of the Company and for preventing and detecting fraud and other
irregularities;

(d) The annual accounts have been prepared on a going concern basis;

(e) Proper internal financial controls were followed by the Company and such internal
financial controls are adequate and were operating effectively;

(f) Proper systems are devised to ensure compliance with the provisions of all applicable
laws and that such systems are adequate and operating effectively.

49. ACKNOWLEDGEMENT

Your Directors takes opportunity to show gratitude towards the assistance and co¬
operation received from Shareholders.

For and on Behalf of the Board of Directors of
Checkpoint Trends Limited
(formerly known as Rubra Medicaments Limited)

Abha Kapoor Gopal Kumar Sahu
Place: Mumbai Whole time Director and CFO Director

Date: September 05, 2024 DIN: 02799429 DIN: 08478039